Abbott Laboratories Return on Tangible Equity 2010-2023 | ABT
Current and historical return on tangible equity values for Abbott Laboratories (ABT) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Abbott Laboratories Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2023-12-31 | $5.72B | $6.33B | 114.01% |
| 2023-09-30 | $5.16B | $5.14B | 118.68% |
| 2023-06-30 | $5.16B | $4.31B | 137.51% |
| 2023-03-31 | $5.80B | $4.30B | 177.48% |
| 2022-12-31 | $6.93B | $3.65B | 307.89% |
| 2022-09-30 | $7.89B | $2.75B | 583.40% |
| 2022-06-30 | $8.55B | $2.38B | 4987.76% |
| 2022-03-31 | $7.73B | $0.23B | -639.62% |
| 2021-12-31 | $7.07B | $0.05B | -320.21% |
| 2021-09-30 | $7.24B | $-1.97B | -201.05% |
| 2021-06-30 | $6.38B | $-3.14B | -131.53% |
| 2021-03-31 | $5.72B | $-3.78B | -94.14% |
| 2020-12-31 | $4.50B | $-5.53B | -61.35% |
| 2020-09-30 | $3.38B | $-6.95B | -41.37% |
| 2020-06-30 | $3.11B | $-8.07B | -36.33% |
| 2020-03-31 | $3.58B | $-8.77B | -40.10% |
| 2019-12-31 | $3.69B | $-8.92B | -39.34% |
| 2019-09-30 | $3.29B | $-8.49B | -32.88% |
| 2019-06-30 | $2.90B | $-9.53B | -26.59% |
| 2019-03-31 | $2.62B | $-10.55B | -22.29% |
| 2018-12-31 | $2.37B | $-11.47B | -18.92% |
| 2018-09-30 | $0.89B | $-12.00B | -6.69% |
| 2018-06-30 | $0.93B | $-13.02B | -7.50% |
| 2018-03-31 | $0.48B | $-13.57B | -4.20% |
| 2017-12-31 | $0.48B | $-14.40B | -4.65% |
| 2017-09-30 | $2.10B | $-8.43B | -46.38% |
| 2017-06-30 | $1.17B | $-9.00B | -359.48% |
| 2017-03-31 | $1.50B | $-9.21B | 44.78% |
| 2016-12-31 | $1.40B | $8.50B | 19.83% |
| 2016-09-30 | $1.37B | $8.41B | 21.16% |
| 2016-06-30 | $2.28B | $5.73B | 39.46% |
| 2016-03-31 | $2.45B | $5.61B | 39.46% |
| 2015-12-31 | $4.42B | $6.13B | 69.79% |
| 2015-09-30 | $4.56B | $5.63B | 74.17% |
| 2015-06-30 | $4.52B | $7.45B | 70.00% |
| 2015-03-31 | $4.20B | $6.15B | 62.46% |
| 2014-12-31 | $2.28B | $5.37B | 31.67% |
| 2014-09-30 | $1.97B | $6.85B | 23.70% |
| 2014-06-30 | $2.40B | $8.53B | 27.78% |
| 2014-03-31 | $2.41B | $8.10B | 28.81% |
| 2013-12-31 | $2.58B | $9.76B | 31.68% |
| 2013-09-30 | $3.04B | $8.14B | 48.21% |
| 2013-06-30 | $4.02B | $7.43B | 82.32% |
| 2013-03-31 | $5.27B | $7.20B | 170.94% |
| 2012-12-31 | $5.96B | $2.45B | 480.21% |
| 2012-09-30 | $6.53B | $2.44B | 1938.83% |
| 2012-06-30 | $4.89B | $0.23B | -571.14% |
| 2012-03-31 | $5.11B | $-0.15B | -359.46% |
| 2011-12-31 | $4.73B | $-1.17B | -196.08% |
| 2011-09-30 | $4.55B | $-2.34B | -131.96% |
| 2011-06-30 | $5.14B | $-2.03B | -111.53% |
| 2011-03-31 | $4.49B | $-4.12B | -85.92% |
| 2010-12-31 | $4.63B | $-5.32B | -86.34% |
| 2010-09-30 | $4.73B | $-6.97B | -152.11% |
| 2010-06-30 | $5.31B | $-4.49B | -839.83% |
| 2010-03-31 | $5.31B | $-4.66B | 579.54% |
| 2009-12-31 | $5.75B | $3.70B | 267.47% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $185.422B | $40.109B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stryker (SYK) | United States | $128.275B | 31.81 |
| Boston Scientific (BSX) | United States | $107.479B | 34.23 |
| Medtronic (MDT) | Ireland | $105.230B | 14.90 |
| EssilorLuxottica (ESLOY) | France | $98.467B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.075B | 0.00 |
| Haleon (HLN) | United Kingdom | $38.356B | 30.00 |
| ResMed (RMD) | United States | $26.979B | 25.30 |
| Terumo (TRUMY) | Japan | $24.775B | 34.99 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.604B | 15.84 |
| Baxter (BAX) | United States | $20.430B | 14.90 |
| Koninklijke Philips (PHG) | Netherlands | $19.242B | 15.35 |
| Insulet (PODD) | United States | $11.496B | 60.36 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.440B | 0.00 |
| Demant (WILYY) | Denmark | $9.943B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.860B | 23.42 |
| BellRing Brands (BRBR) | United States | $7.238B | 38.92 |
| Lantheus Holdings (LNTH) | United States | $4.470B | 11.54 |
| Haemonetics (HAE) | United States | $4.452B | 22.77 |
| Perrigo (PRGO) | Ireland | $4.238B | 12.12 |
| GN Store Nord (GNNDY) | Denmark | $3.889B | 25.18 |
| Prestige Consumer Healthcare (PBH) | United States | $3.482B | 16.47 |
| Envista Holdings (NVST) | United States | $3.441B | 13.09 |
| QuidelOrtho (QDEL) | United States | $2.654B | 9.63 |
| Neogen (NEOG) | United States | $2.591B | 24.92 |
| Green Thumb Industries (GTBIF) | United States | $2.482B | 78.67 |
| ICU Medical (ICUI) | United States | $2.303B | 17.19 |
| TG Therapeutics (TGTX) | United States | $2.150B | 695.50 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.906B | 0.00 |
| Owens & Minor (OMI) | United States | $1.848B | 17.74 |
| Agios Pharmaceuticals (AGIO) | United States | $1.780B | 0.00 |
| Verano Holdings (VRNOF) | United States | $1.617B | 0.00 |
| InMode (INMD) | Israel | $1.429B | 7.40 |
| LeMaitre Vascular (LMAT) | United States | $1.414B | 46.66 |
| National Vision Holdings (EYE) | United States | $1.399B | 43.58 |
| AdaptHealth (AHCO) | United States | $1.273B | 9.58 |
| Warby Parker (WRBY) | United States | $1.254B | 0.00 |
| AtriCure (ATRC) | United States | $1.094B | 0.00 |
| MacroGenics (MGNX) | United States | $0.899B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.872B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.764B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.686B | 14.82 |
| Cresco Labs (CRLBF) | United States | $0.674B | 0.00 |
| Evolus (EOLS) | United States | $0.664B | 0.00 |
| Jin Medical (ZJYL) | China | $0.608B | 0.00 |
| Quanterix (QTRX) | United States | $0.596B | 0.00 |
| Valneva SE (VALN) | France | $0.526B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.504B | 10.91 |
| PetIQ (PETQ) | United States | $0.480B | 17.93 |
| TerrAscend (TSNDF) | Canada | $0.462B | 0.00 |
| ZimVie (ZIMV) | United States | $0.421B | 25.80 |
| Biote (BTMD) | United States | $0.416B | 3.96 |
| OraSure Technologies (OSUR) | United States | $0.402B | 6.66 |
| Surmodics (SRDX) | United States | $0.373B | 40.26 |
| Aurora Cannabis (ACB) | Canada | $0.366B | 0.00 |
| Zynex (ZYXI) | United States | $0.352B | 40.52 |
| Viemed Healthcare (VMD) | United States | $0.310B | 30.81 |
| Cerus (CERS) | United States | $0.308B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.278B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.266B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.238B | 14.73 |
| Organigram Holdings (OGI) | Canada | $0.192B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.178B | 0.00 |
| Omeros (OMER) | United States | $0.177B | 0.00 |
| Veru (VERU) | United States | $0.177B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.162B | 0.00 |
| High Tide (HITI) | Canada | $0.161B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.156B | 0.00 |
| Eagleford Energy (GRUSF) | United States | $0.141B | 70.99 |
| FitLife Brands (FTLF) | United States | $0.129B | 20.74 |
| Jushi Holdings (JUSHF) | United States | $0.125B | 0.00 |
| InterCure (INCR) | Israel | $0.120B | 20.31 |
| Fonar (FONR) | United States | $0.107B | 9.16 |
| MariMed (MRMD) | United States | $0.100B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.097B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.089B | 0.00 |
| Safety Shot (SHOT) | United States | $0.082B | 0.00 |
| Brainsway (BWAY) | Israel | $0.080B | 0.00 |
| Chimerix (CMRX) | United States | $0.079B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.059B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.055B | 3.59 |
| Apyx Medical (APYX) | United States | $0.051B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.044B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.044B | 0.00 |
| ImmuCell (ICCC) | United States | $0.040B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 14.95 |
| Bright Green (BGXX) | United States | $0.035B | 0.00 |
| Modular Medical (MODD) | United States | $0.033B | 0.00 |
| Exagen (XGN) | United States | $0.024B | 0.00 |
| Nephros (NEPH) | United States | $0.023B | 0.00 |
| Flora Growth (FLGC) | United States | $0.020B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.019B | 0.00 |
| Agape ATP (ATPC) | $0.019B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.017B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.012B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.010B | 74.09 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.008B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.004B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.003B | 0.00 |
| Lucy Scientific Discovery (LSDI) | Canada | $0.002B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.001B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| Bruush Oral Care (BRSH) | $0.000B | 0.00 | |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |